Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Gene Copy Number Determination – V 2.0

Posted on By


Biosimilars: SOP for Gene Copy Number Determination – V 2.0


Standard Operating Procedure for Gene Copy Number Determination in Biosimilar Cell Lines

Department Biosimilars
SOP No. SOP/BS/017/2025
Supersedes SOP/BS/017/2022
Page No. Page 1 of 13
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a standardized method for determining the gene copy number of integrated biosimilar transgenes in cell lines using quantitative PCR (qPCR), aiding in clone selection and stability assessment.

2. Scope

This SOP applies to molecular biology and analytical development teams responsible for evaluating and validating biosimilar-producing clones through gene copy number quantification.

3. Responsibilities

  • Molecular Biologist: Conducts DNA extraction, qPCR setup, and data analysis.
  • Research Associate: Assists in sample preparation and maintains documentation.
  • QA Officer: Verifies results and checks data integrity for regulatory compliance.

4. Accountability

The Head of Molecular Biology is accountable for ensuring accuracy and reproducibility of gene copy number data in biosimilar cell line evaluations.

5. Procedure

5.1 Genomic DNA Extraction

  1. Harvest cells (≥1 × 106) and wash with PBS.
  2. Extract DNA using silica column-based kits or phenol-chloroform method.
  3. Quantify and assess DNA purity using spectrophotometer (A260/A280 ratio 1.8–2.0).

5.2 Primer and Probe Design

  1. Design primers targeting a region of the biosimilar transgene (e.g., Fc region for mAb genes).
  2. Select a single-copy reference gene (e.g., β-actin or GAPDH).
  3. Validate primer efficiency (90–110%) and specificity prior to use.

5.3 Real-Time PCR Setup

  1. Prepare 20 µL reactions containing:
    • 10 µL SYBR Green or probe-based master mix
    • 1 µL each of forward and reverse primers (10 µM)
    • 1 µL genomic DNA (10–50 ng)
    • 7 µL nuclease-free water
  2. Run samples in triplicates on a real-time PCR machine (e.g., ABI 7500).
  3. Thermal cycling conditions:
    • Initial denaturation: 95°C for 10 min
    • 40 cycles: 95°C for 15 sec, 60°C for 60 sec

5.4 Data Analysis

  1. Calculate ΔCt = Cttransgene – Ctreference.
  2. Relative copy number = 2-ΔΔCt compared to control clone or calibrator.
  3. Include positive control (known copy number) and no template control (NTC).
  4. Document results in Gene Copy Number Log (Annexure-1).

5.5 Acceptance Criteria

  1. Coefficient of variation (CV) among replicates should be ≤5%.
  2. Reference gene Ct range: 18–25.
  3. Transgene Ct range: 18–30 depending on copy number.

6. Abbreviations

  • qPCR: Quantitative Polymerase Chain Reaction
  • DNA: Deoxyribonucleic Acid
  • Ct: Cycle Threshold
  • ΔCt: Difference in Ct values between target and reference genes

7. Documents

  1. Gene Copy Number Log (Annexure-1)
  2. qPCR Plate Map (Annexure-2)

8. References

  • ICH Q6B – Test Procedures and Acceptance Criteria
  • WHO TRS 1004 – Guidelines on Molecular Characterization
  • MIQE Guidelines – Minimum Information for Publication of qPCR Experiments

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Gene Copy Number Log

Date Clone ID Ct (Target) Ct (Reference) ΔCt Copy Number Operator
03/05/2025 CL-BS-017 22.6 19.1 3.5 8 Sunita Reddy

Annexure-2: qPCR Plate Map

Well Sample ID Target Gene Reference Gene Replicate
A1 CL-BS-017 rhEGFR GAPDH 1
A2 CL-BS-017 rhEGFR GAPDH 2
A3 CL-BS-017 rhEGFR GAPDH 3

Revision History:

Revision Date Revision No. Details Reason for Revision Approved By
04/05/2025 2.0 Updated primer efficiency criteria and added plate map annexure Annual Review
See also  Biosimilars: SOP for Viral Filtration Using 20 nm Filters - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Elixir Department: SOP for Cleaning of Dispensing Area Before and After Use – V 2.0
Next Post: API Manufacturing: SOP for Monitoring of Solvent Recovery Efficiency – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version